Searchable abstracts of presentations at key conferences in endocrinology

ea0022s10.3 | Novel aspects in the treatment of bone disease | ECE2010

Teriparatide and parathyroid hormone in the treatment of ostoporosis

Kraenzlin Marius E

The pharmacologic armamentarium available to clinicians to reduce fracture risk in women with postmenopausal osteoporosis consists essentially of antiresorptive agent. Recently, peptides from the parathyroid hormone (PTH) family, which under specific modalities of administration act as anabolic agents have become available. The interest generated by these alternatives to antiresorptive treatment resides in their greater potential for restauration of bone mass and possibly also...

ea0020p229 | Bone/Calcium | ECE2009

Swiss primary hyperparathyroidism cohort study

Trombetti Andrea , Meier Christian , Kraenzlin Marius E , Herrmann Francois R , Henzen Christoph H , Christ Emmanuel R , Brandle Michael , Rizzoli Rene

Objective: The Swiss Primary HyperParaThyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional project collecting clinical, densitometric, biochemical and outcome data in patients with PHPT. The aims are to describe the profile of these patients particularly neurobehavioral and cognitive symptoms, changes in calcium and PTH over time and treatment modalities.Methods: Patients newly diagnosed with PHPT and with high serum calcium leve...